Targeting ALK, ROS1, and BRAF kinases.

J Thorac Oncol

Division of Medical Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.

Published: December 2012

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155403PMC
http://dx.doi.org/10.1097/JTO.0b013e31826df05eDOI Listing

Publication Analysis

Top Keywords

targeting alk
4
alk ros1
4
ros1 braf
4
braf kinases
4
targeting
1
ros1
1
braf
1
kinases
1

Similar Publications

Recommendations to address the shortfalls of the EAT-Lancet planetary health diet from a plant-forward perspective.

Lancet Planet Health

January 2025

Department of Agricultural Economics and Rural Development, University of Göttingen, Göttingen, Germany; Department of Nutrition, Fulda University of Applied Sciences, Fulda, Germany.

Shifting to dietary patterns rich in plants and low in animal-source foods could substantially lower emissions from the food sector while reducing the global burden of non-communicable diseases. The EAT-Lancet Commission proposed the planetary health diet (PHD) to emphasise plant-forward diets and set global targets to guide an urgently needed food-system transformation. However, the PHD's meat-reduction approach has attracted criticism and prompted debate on the potential micronutrient shortfalls of the plant-forward dietary approach.

View Article and Find Full Text PDF

Treatment options for patients with relapsed or refractory (R/R) anaplastic large cell lymphoma (ALCL) have increased in the era of targeted therapies such as brentuximab vedotin (BV) and Anaplastic Lymphoma Kinase (ALK) inhibitors. However, there is no standard treatment and limited published data evaluating their use. The goal of this retrospective study is to describe current real-world treatment and outcomes of pediatric, adolescent, and young adult patients with R/R ALK-positive ALCL.

View Article and Find Full Text PDF

TET2-mediated 5-hydroxymethylcytosine of TXNIP promotes cell cycle arrest in systemic anaplastic large cell lymphoma.

Clin Epigenetics

January 2025

Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.

Background: 5-Hydroxymethylcytosine (5hmC) modification represents a significant epigenetic modification within DNA, playing a pivotal role in a range of biological processes associated with various types of cancer. The role of 5hmC in systemic anaplastic large cell lymphoma (ALCL) has not been thoroughly investigated. This study aims to examine the function of 5hmC in the advancement of ALCL.

View Article and Find Full Text PDF

The anaplastic lymphoma kinase (ALK) oncoprotein plays a crucial role in non-small cell lung cancer (NSCLC) by activating signaling pathways involved in cell proliferation and survival through constitutive phosphorylation. While first-line crizotinib can regulate phosphorylation, mutations in the ALK gene can lead to resistance against ALK inhibitors (ALKi) such as ceritinib and alectinib. On the other hand, overexpression of BCL2, a protein involved in cell death regulation, has been observed in NSCLC and is considered a potential therapeutic target.

View Article and Find Full Text PDF

Lung cancer is a malignant tumor with high morbidity and mortality in China and worldwide. Once it metastasizes to the brain, its prognosis is very poor. Brain metastases are found in about 20% of newly diagnosed non-small-cell lung cancer (NSCLC) patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!